Vitamin, Mineral and Amino Acid Supplement
98/100
This product looks safe
- Niacin: 74mg is 2.1× the Tolerable Upper Intake Level (35mg)
- 61% of ingredients have research evidence
C
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
⚠️ Niacin: 74mg is 2.1× the Tolerable Upper Intake Level (35mg)
Label Data
1 Packet(s)
Serving Size
30
Servings
Other Combinations
Product Type
61%
Evidence Coverage
Supplement Facts — Evidence Check
Calories
50 {Calories}
Total Carbohydrates
12 Gram(s)
(4% DV)
Protein
1 Gram(s)
(2% DV)
Vitamin C
324 mg
(540% DV)
15 IU
(50% DV)
✅ Within RDA (0.7× RDA of 15 mg)
📚 177 studies (Tier A: 3, B: 90)
1.5 mg
(100% DV)
✅ 1.2× RDA — within safe limits
📚 76 studies (Tier A: 0, B: 33)
3 mg
(176% DV)
✅ 2.3× RDA — within safe limits
📚 12 studies (Tier A: 0, B: 1)
74 mg
(370% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.1× (UL: 35 mg)
📚 193 studies (Tier A: 5, B: 63)
16 mg
(800% DV)
📊 12.3× RDA — above typical dose (UL: 100 mg)
📚 113 studies (Tier A: 3, B: 35)
100 mcg
(25% DV)
✅ Within RDA (0.2× RDA of 0.4 mg)
📚 225 studies (Tier A: 10, B: 105)
20.2 mcg
(337% DV)
📊 8.4× RDA — above typical dose
📚 138 studies (Tier A: 1, B: 44)
18 mg
(184% DV)
📊 3.6× RDA — above typical dose
📚 1 studies — no high-quality reviews
3 mg
(21% DV)
✅ Within RDA (0.3× RDA of 11 mg)
📚 258 studies (Tier A: 6, B: 134)
0.4 mg
(21% DV)
✅ Within RDA (0.4× RDA of 0.9 mg)
📚 36 studies (Tier A: 0, B: 11)
25 mcg
(21% DV)
✅ Within RDA (0.7× RDA of 0.035 mg)
📚 197 studies (Tier A: 1, B: 55)
L-Phenylalanine
505 mg
202 mg
📊 Market median: 500.0mg (180 products)
📚 5 studies (Tier A: 0, B: 1)
Glycine
151 mg
Label Claims — Verification
❓
No Claim
All Other (98% of products)
Structure/Function (78% of products)
Nutrient (56% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
Additional Information
Natural & Artificial Orange Flavored
30 packs of 0.44 oz
Product Details
Research Evidence
50
Research Sources
47
Avg Quality Score
28
Rct
13
Clinical Trial
5
Guideline
4
Systematic Review
A
Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.
B
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.
B
Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates
B
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].
B
[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].
B
Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.
B
Baseline-dependent effect of dopamine's precursor L-tyrosine on working memory gating but not updating
C
Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression
